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ABSTRACT 
This paper describes a synthetic dimer of carbonic anhydrase, and a series of bivalent 
sulfonamide ligands with different lengths (25 to 69 Å between the ends of the fully 
extended ligands), as a model system to use in examining the binding of bivalent 
antibodies to antigens.  Assays based on analytical ultracentrifugation and fluorescence 
binding indicate that this system forms cyclic, noncovalent complexes with a 
stoichiometry of one bivalent ligand to one dimer.  This dimer binds the series of bivalent 
ligands with low picomolar avidities (Kd
avidity = 3 – 40 pM).  A structurally analogous 
monovalent ligand binds to one active site of the dimer with Kd
mono = 16 nM.  The 
bivalent association is thus significantly stronger (Kd
mono / Kd
avidity ranging from ~500 to 
5000 unitless) than the monovalent association.  We infer from these results, and by 
comparison of these results to previous studies, that bivalency in antibodies can lead to 
associations much tighter than monovalent associations (although the observed bivalent 
association is much weaker than predicted from the simplest level of theory—predicted 
Kd
avidity of ~ 0.002 pM and Kd
mono / Kd
avidity ~ 8 × 10
6 unitless).    3 
INTRODUCTION 
  Although antibodies are centrally important components of the immune systems 
of vertebrates
1 we understand little about the thermodynamics of these proteins binding to 
their antigens.
2  We know surprisingly little about the reasons antibodies have the 
structures they do; in particular, the reasons that the binding regions of all antibodies are 
dimers (i.e., two Fab domains), or multiples of dimers.  Why dimers?  Why not a tightly 
binding monomer?  Or a trimer?  There is no clear molecular rationale that leads to the 
conclusion that two Fab regions provide the best Darwinian solution to the problems in 
“molecular defense” posed to the immune system.   
  In trying to understand why all antibodies have at least two binding sites, we want 
to understand, quantitatively, the thermodynamics of association between antibodies and 
their antigens (both monovalent and polyvalent).  Understanding the mechanism and 
thermodynamics that determines the free energy of the association between antibodies 
and multivalent antigens could, we believe, serve three purposes: i) it could help to 
answer the biochemical question of the reason for bi- or oligovalency in antibodies,
3 ii) it 
could contribute broadly to understanding oligovalency in molecular biology,
4,5 iii) it 
could help in the design of inhibitors of oligovalent interactions, including those 
involving antibodies.
6,7  In particular, we are interested in the advantage, if any, that 
bivalency in antibodies affords to the thermodynamics of binding to antigen over that of a 
monovalent interaction—that of Fab to antigen.   
  This paper describes a system—a synthetic dimer of carbonic anhydrase (which 
we call a “dimer of CA”, or “(CA)2”) and a series of bivalent benzenesulfonamides 
connected by oligo-sarcosine linkers (LRL where L is a derivative of   4 
benzenesulfonamide)—that we use to model the thermodynamics of association between 
bivalent antibodies and multivalent antigens (Scheme 1).  This synthetic dimer of CA is 
inspired by the structure of immunoglobulins, and formed by linking two site-specific 
mutants of human carbonic anhydrase II (HCAII, EC 4.2.1.1) (Figure 1).  We test the 
influence of the length of the oligo-sarcosine linker joining the two sulfonamide moieties 
(LRL) on the strength of the interaction between the synthetic dimer of CA and these 
sulfonamide ligands.      
  We recently reported that dimers of CA bound less strongly to ligands 
immobilized on a surface than would be expected from a simple theory.
3  This theory 
predicts the change in free energy (ΔG°avidity) for the bivalent association of (CA)2 to 
bivalent ligands would be twice the change in enthalpy for the monovalent interaction 
(ΔH°mono) plus the change in entropy for a single monovalent interaction (TΔS°mono) (eq 
1).
8  In this work, we designed and synthesized a series of bivalent ligands (LRL) with   
mono mono avidity T 2 ° Δ − ° Δ = ° Δ S H G              (1) 
the goal of maximizing the strength of association between LRL and (CA)2.  
Surprisingly, but also consistent with our previous findings, the strength of association of 
these ligands to (CA)2 (ΔG°avidity ranging from –14 to –16 kcal mol
–1) is again much less 
than the simplest theory  predicts (predicted ΔG°avidity = –19 kcal mol
-1).  Additionally, 
we found that varying the length of the linker connecting the arylsulfonamides led only to 
small, but significant, differences in the free energies of bivalent binding of LRL to 
(CA)2: the free energies of binding for six bivalent ligands to (CA)2 (ΔG°avidity ranging 
from –14 to –16 kcal mol
-1) were all within 2 kcal mol
-1 of each other, despite an end-to-
end distance ranging from 31 Å to 69 Å (21 to 41 rotatable bonds).    5 
  Schweitzer-Stenner and coworkers quantified the association between monoclonal 
anti-DNP IgE and a series of bivalent DNP ligands of different lengths (14 Å to 160 Å) 
using fluorescence titrations.
9  They inferred that the longer ligands (145 Å and 160 Å) 
were capable of binding bivalently, although weakly, to IgE (enhancements, defined as 
Kd
mono / Kd
avidity, of 7 to 20 unitless), while the shorter ligands (<132 Å) formed cyclic 
complexes comprising two antibodies and two ligands with enhancements of 100 to 600.  
In a series of papers, the Baird group quantified the interaction of antibodies and 
multivalent ligands often using bivalent DNP ligands, anti-DNP IgE, and cells.
10-12  In 
one of these studies, Das and coworkers reported the synthesis of a series of bivalent 
DNP ligands with poly(ethylene glycol) (PEG) linkers (1, 3, and 10 kDa) and 
characterized their association to monoclonal anti-DNP IgE.
13  They found that cyclic, 
bivalent complexes can form from the combination of one bivalent ligand and one IgE 
and observed enhancements of 10 to 300.  These results are consistent with those of 
Schweitzer-Stenner: “long” ligands can bridge the binding sites of single antibody and 
form intramolecularly-bound, cyclic complexes of one antibody and one L2.  In related 
work, we characterized the complexes formed from mixtures of monoclonal anti-DNP 
IgG and a synthetic trivalent DNP ligand.
14  We characterized the stability of these 
species and found that complexes of two trivalent ligands (L3) and three antibodies can 
form in a yield of ~ 90% with an enhancement of ~50.   
  Bivalent Benzenesulfonamide Ligands LRL and (CA)2 Model Bivalency in 
Antibodies.  We are interested in defining the advantages that bivalent antibodies have 
over their monovalent counterparts, the Fab domain, both in vivo and in vitro, because we 
wish to modulate (to inhibit or to enhance) their binding to antigens.
15  We intend the   6 
combination of (CA)2 and LRL to serve as a model with which to examine the biophysics 
and physical-organic chemistry of bivalency in antibodies.  This combination of (CA)2 
and bivalent sulfonamides is particularly well-suited as a model for bivalent interactions 
for at least seven reasons: i) The carbonic anhydrase dimer has the essential structural 
features of IgG:  The dimer consists of two identical binding domains linked by a flexible 
chain.  IgG consists of two identical binding domains linked by two flexible chains to an 
Fc domain.  We can easily change the nature of the linkers (length and flexibility) 
connecting the binding sites in the dimers.
3  These sorts of changes would require major 
efforts in mutagenesis to carry out on any IgG.  ii) The carbonic anhydrases (HCA I (28.8 
kDa), HCA II (29.2 kDa), and bovine carbonic anhydrase BCA II (29.1 kDa), which 
differ only by 382 Da) are similar in size to the Fabs of IgG (~50 kDa).  iii) HCA is 
structurally stable and readily available.
16-19 HCA is available in quantities of hundreds of 
milligrams from E. coli with the investment of a few days of work and a minimal cost of 
supplies.  Commercially available monoclonal antibodies (for example, monoclonal anti-
DNP antibodies) cost in the range of ~100$ per 0.1 mg.  At that cost, conducting a panel 
of experiments with different ligands—and with enough repeats to provide estimates of 
uncertainties—would be very expensive (>$10,000).  iv) HCA is easily modified by site-
directed mutagenesis. Antibodies are available through site-directed mutagenesis, but 
their expression from yeast, insect, or mammalian cells is much more challenging and 
available in fewer academic groups (especially those of physical-organic chemists) than 
the expression and purification of proteins from E. coli.   v)  Numerous arylsulfonamides 
of the general structure R-Ar-SO2NH2 bind to HCA in a conserved and well characterized 
geometry.
20  The geometry of the sulfonamide ligands in the active site of CA is as well   7 
defined as that of any ligand for any protein; there is no corresponding information on 
what would happen to a ligand in the binding site of a Fab, especially if we changed the 
structure of the ligand.
21  We can think of no monoclonal antibody that has a set of 
ligands with properties as varied and as well characterized as the ones that bind to CA.  
vi) Synthesis of sulfonamide ligands which bind to CA is tractable, as is their 
incorporation in bi- and oligovalent systems.  vii) The literature in assays for CA—from 
enzymatic through fluorescence to surface plasmon resonance and capillary 
electrophoresis—is much richer for CA than for IgGs.  We believe HCA is an excellent 
model protein—the best we know—for physical-organic studies of protein-ligand 
binding.
21 
  The CA-Arylsulfonamide Interaction.  The carbonic anhydrases bind a wide 
range of ligands including, arylsulfonamides, with dissociation constants (Kd
mono) in the 
range of micromolar to picomolar.
20,21  The equilibrium for a monovalent ligand (L), a 
monomeric carbonic anhydrase (CA), and a CA-ligand complex (CA·L) is characterized 
by the monovalent affinity of the interaction, Kd
mono (eq 2 and Scheme 1a).  
 
] CA·L [
] L ][ CA [ mono
d = K                 (2) 
  ) ( ln    RT
mono
d mono K G = ° Δ
             
(3) 
  Intramolecular Binding of a Tethered Ligand-CA System.  In studies aimed at 
understanding intramolecular interactions, we characterized the thermodynamics of 
binding for the association between the active site of CA and an arylsulfonamide ligand 
that was covalently tethered to the surface of HCA by oligo(ethylene glycol) linkers of 
different lengths (EGn, n = 0, 2, 5, 10, and 20; Chart1 and Scheme1b).
22  We 
characterized the strength of the intramolecular bond using a unitless dissociation   8 
constant Kd
intra —the ratio of the concentrations of CA−L
lin to CA−L
cyc (eq 4, where the 
hyphen represents the covalent attachment between L and CA).       
 
] L _ CA [
] L _ CA [
cyc
lin
intra
d = K                  (4) 
  ) ( ln    RT
intra
d intra K G = ° Δ               (5) 
  In that system, the relationship between the intramolecular dissociation constant 
(values of Meff  ranging from 0.8 to 26 mM) and the length of the flexible linker (ranging 
from 25 to 105 Å in extended length between the nitrogen of the sulfonamide and the 
disulfide bond connecting ligand to the protein) was quantitatively well-explained by a 
model that describes the linker as a random-coil polymer (eq 6 and Table 1).  We inferred  
 
intra
d
inter
d eff /K K M =                  (6) 
from calorimetric studies that the length of the linker influenced the thermodynamics of 
binding exclusively entropically.
22   
  Dimers of CA Bind to Mixed SAMs Presenting Benzenesulfonamides.   In 
studies aimed at understanding the binding of bivalent proteins to ligands on a surface, 
we developed five synthetic dimers of carbonic anhydrase and studied their interaction 
with benzenesulfonamide ligands presented at the surface of mixed self-assembled 
monolayers (SAMs) (Scheme 1c).
3  We prepared three dimers of CA having different 
lengths of the oligo(ethylene glycol) linker that joined the two molecules of CA, and two 
dimers with different points of attachment of the linker to the protein.  We found that the 
dimers of CA bound bivalently to the SAM with low nanomolar avidities (Kd
avidity, surf = 1 
– 3 nM, Meff = 3 to 20 µM) while monomeric carbonic anhydrase (CA) bound to the 
ligands of the SAM less strongly (Kd
surf = 89 nM).  The bivalent binding of these dimers   9 
to the SAM represents a modest ~50-fold enhancement of bivalent over monovalent 
association.  The avidity of these bivalent proteins were unexpectedly insensitive to the 
structure of the linker connecting them: changing the length of the linker with end-to-end 
distances between 9 and 18 Å, or the point of attachment between the molecules of CA 
(either near the active site (C133) or distal to the active site (C185)) had virtually no 
effect on the avidity of these dimers for the SAM.   
  Bivalent Interactions in Protein-Ligand Systems.  In this paper, we focus on 
differences in the free energy (ΔG°) of binding of mono- and bivalent ligands to CA, and 
to a dimer of CA (Scheme 1a and 1d).  Scheme 1d diagrams the association of (CA)2 and 
LRL as a process that involves two steps.  Equation 7 (by analogy to equation 3) 
describes the equilibrium constant for the association of LRL to (CA)2.  A dimer of CA is  
] LRL (CA) [
] LRL ][ (CA) [
) 4 / 1 ( lin
2
2 inter
d ⋅
= K             (7) 
statistically four times more likely to bind a bivalent ligand as monomeric CA is to bind a 
monovalent ligand because (CA)2 has two binding sites and LRL has two ligand moieties 
that can bind to CA.
23  The value of Kd
inter determines the change in free energy for the 
monovalent binding of (CA)2 to LRL (eq 8).   
  ) ( ln    RT
inter
d inter K G = ° Δ               (8) 
  A dimer of CA can, in principle, form an intramolecular noncovalent bond with a 
bivalent ligand in which the unoccupied active site of (CA)2·LRL
lin binds the second 
sulfonamide of LRL and forms (CA)2·LRL
cyc (Scheme 1d).  At equilibrium, 2 Kd
intra 
equals the concentration of (CA)2·LRL
lin divided by the concentration of (CA)2·LRL
cyc 
(eq 9).
24   10 
     
] LRL (CA) [
] LRL (CA) [
2 cyc
2
lin
2 intra
d ⋅
⋅
= K             (9) 
The overall strength of association between (CA)2 and LRL is characterized by the 
avidity of this bivalent interaction (Kd
avidity, M) (eq 10 and Scheme 1d).   
intra
d
inter
d cyc
2
2 avidity
d   2     (1/4)    
] LRL   (CA) [
] LRL ][ (CA) [
K K K ⋅ =
⋅
=          (10) 
It follows from equations 2 and 5 that the change in free energy for the formation of a 
cyclic, bivalently bound structure (CA)2·LRL
cyc (ΔG°avidity) is given by equation 11.   
  ) ( ln    RT
avidity
d avidity K G = ° Δ               (11)       
  The enhancement (β) is the ratio of the monovalent dissociation constant to the 
avidity, and can describe an increase or decrease in the strength of binding between 
(CA)2 and LRL relative to that of CA and L (eq 12).
15  Values of β > 1 indicate that  
 
  avidity
d
mono
d
K
K
= β
                 
(12) 
(CA)2 binds to LRL more strongly than (CA)2 binds to L.  
  
EXPERIMENTAL DESIGN 
  To characterize the binding of the dimer of CA to the series of bivalent ligands, 
we estimated values of ΔG°avidity, because comparison of ΔG°avidity with ΔG°mono 
describes the energetic consequence of tethering together two benzenesulfonamides 
(here, with an oligo-sarcosine linker).  In particular, we wanted to determine the 
dependence of ΔG°avidity—our metric for the strength of bivalent binding—on the length 
of the linker joining the two benzenesulfonamides of the ligand.      
We synthesized bivalent derivatives of benzenesulfonamides with oligo-sarcosine   11 
linkers with 0, 2, 4, 6, 8, 10 sarcosine units (LSarnL in Chart 1).  We chose oligo-
sarcosines as the linkers because they are typically more soluble in aqueous solutions 
than other peptides.
25 Oligomers of sarcosine show little non-specific binding to proteins 
because the N-methyl group prevents hydrogen bonding between the nitrogen of the 
amide and the carbonyl oxygens of the protein.
26,27  We selected the number of sarcosine 
units comprising the different linkers (n = 0, 2, 4, 6, 8, 10) to provide lengths (31 to 69 Å) 
that range from “similar to”, to “larger than”, the minimum distance required to bridge 
the active sites of the dimer of CA (~30 Å).  We also employed a short bivalent ligand 
(25 Å) with a tri(ethylene glycol) linker (LEG3L in Chart 1).  We hypothesized that 
LEG3L would not bind bivalently to the dimer of CA, because this ligand is shorter than 
the minimum distance between the binding sites of the dimer.  We used LEG3L as a 
control of monovalent binding to which we compared the longer ligands of LSarnL. 
Numerous complexes defined by different stoichiometries—represented by 
((CA)2)n·(LRL)m—can, in principle, form from mixtures of (CA)2 and LRL.
28  The 
tendency of multivalent systems of receptors and ligands to form complexes of different 
stoichiometry in the same solution, coupled with the difficulties in determining which 
complexes are formed, represents a significant barrier in the determination of the free 
energies of association of multivalent interactions.  We conducted two assays (analytical 
ultracentrifugation (AUC) and a kinetic assay based on observing the dissociation of LRL 
from (CA)2) that allowed us to determine the stoichiometry of ((CA)2)n·(LRL)m 
complexes.  We used this information to construct a mathematical model that we fit to the 
data from a fluorescence displacement assay, ultimately extracting values of ΔG°avidity for 
the series of LRL binding to (CA)2.    12 
Analytical ultracentrifugation (AUC) is a solution technique that provides an 
estimate of the molecular weights of proteins and their complexes with ligands.
29  We 
used AUC to estimate the molecular weights of CA, (CA)2, and mixtures of (CA)2 and 
LRL and inferred from these measurements the coefficient n in ((CA)2)n·(LRL)m 
complexes.  We then used the estimate of n to select a set of equations—a mathematical 
model—to describe the fluorescence displacement assay.    
We developed a kinetic assay to follow the rate of dissociation of bivalent ligands 
from (CA)2 in the presence of the monovalent inhibitor ethoxzolamide, which competes 
with LRL for the binding sites of (CA)2.  This kinetic assay makes it possible to 
determine the valency of the interaction between (CA)2 and LRL; that is, to determine the 
presence of intramolecular noncovalent bonds in these complexes.  A dependence of the 
rate of dissociation of LRL from (CA)2 on the concentration of ethoxzolamide 
corresponds to the presence of intramolecular non-covalent bonds in the (CA)2 -LRL 
complexes, vide infra. 
We followed the binding of (CA)2 to bivalent ligands in the presence of the 
monovalent ligand dansylamide using a fluorescence competition assay.  Dansylamide 
(DNSA) is weakly fluorescent in buffered solution, but becomes fluorescent upon 
binding to CA.
30  The intensity of the fluorescence of the solution is therefore 
proportional to the concentration of dimers with DNSA bound in their active sites.  There 
are three advantages to this assay over alternative techniques:  i) it is applicable to a wide 
variety of ligands that bind to the active site of CA, ii) it is applicable to all iso-types of 
CA and its mutants, and iii) it can be described by a mathematical model—i.e., an 
equation can be used to describe the equilibria and mass balance of the system—and can   13 
thus use the data (fluorescence binding isotherms) to provide estimates for the 
dissociation constants and the free energies.
22  Comparison of free energies binding of 
ligands with different lengths of linker to (CA)2 is the focus of this paper.  
 
RESULTS AND DISCUSSION 
  Synthesis and Characterization of Dimers of CA. We previously described the 
preparation of the synthetic dimer of human carbonic anhydrase II ((CA)2) from a double 
mutant of HCAII.
3   
  Preparation of Monovalent and Bivalent Sulfonamides.  We prepared a series 
of bivalent benzenesulfonamide ligands (LRL) with oligo-sarcosine linkers (n = 0, 2, 4, 6, 
8, 10 sarcosine units) using standard techniques of solid-phase peptide synthesis, a 
bivalent ligand with a tri(ethylene glycol) linker, and the monovalent 
benzenesulfonamide ligand L.  We present many of the experimental results as a function 
of the distance between the two nitrogen atoms of the bivalent ligands when the ligands 
are in unstrained conformations that maximize this distance.  We call this maximum 
distance the “extended length of the bivalent ligands”, or Γ.   We calculated Γ from 
molecular models of ligands using the software package Chem3D Pro by Cambridgesoft. 
  (CA)2 and LRL form complexes containing only one (CA)2.  Analytical 
ultracentrifugation (AUC) is a solution technique that provides an estimate for the 
molecular weights of proteins and their complexes with ligands.  AUC is an optical 
technique based on the absorbance of light by the solution of protein.  We required a 
concentration of (CA)2 (925 nM) that would provide a suitable ratio for the signal to 
noise in the instrument, and adjusted the concentration of LRL to maximize ligand-  14 
induced oligomerization.  Dembo and Goldstein reported that the total concentration of 
LRL that maximizes the concentration of complexes with two or more (CA)2’s (that is, 
[LRL]0, max) is a function of the total concentration of bivalent receptors, [R2]0, and the 
dissociation constant Kd
inter  (eq 13).
31  Substituting 16 nM for Kd
inter and  
  0 2
inter
d
max   0, ] [(CA)
2
 
[LRL] + =
K             (13) 
925 nM for [(CA)2]0 gives 960 nM for the total concentration of LRL ([LRL]0, max); this 
concentration of LRL (~1 µM) is the one we used in these experiments.   
  We carried out sedimentation equilibrium experiments on a Beckman XL-I 
ultracentrifuge at rotor speeds of 8,000, 10,000 and 12,000 rpm, at 25 °C in order to 
verify that in mixtures of 925 nM (CA)2 and 1 µM LRL, only complexes containing one 
molecule of (CA)2 are formed at equilibrium (Figure 2).  It is reasonable to assume that 
under these conditions the ligands are bound to active sites of (CA)2.  This procedure 
yielded an estimated molecular weight of 58 ± 4 kDa for (CA)2 (Table S1). This result is 
indistinguishable from the value of 58.385 kDa for (CA)2 determined by mass 
spectrometry.  The results of the AUC experiments support the conclusion that only 
complexes that contain one (CA)2 and one LRL are observed in mixtures of (CA)2 and 
LRL, when the concentration of (CA)2 is 925 nM or less.   
       (CA)2 and LRL dissociate rapidly in the presence of high concentrations of 
ethoxzolamide.  AUC experiments cannot distinguish between complexes of similar 
molecular weight; that is, AUC does not tell us if LRL binds to (CA)2, or if a mixture of 
(CA)2·LRL
lin and 
 (CA)2·LRL
cyc are both present at equilibrium.  We require additional 
structural information on the complexes present at equilibrium in order to construct the   15 
mathematical model that we use to estimate the free energy of association from the 
fluorescence displacement assay.   
  We developed a kinetic assay based on fluorescence spectroscopy and confirmed 
the presence of (CA)2·LRL
cyc by following the rate of dissociation of LSar4L from (CA)2 
in the presence of the soluble monovalent inhibitor, ethoxzolamide, that competes with 
LRL for the binding sites of (CA)2.
3 This assay consists of four steps (Figure 3a).  i) We 
allowed a solution of (CA)2 and LRL to equilibrate in a stirred quartz cuvette while the 
temperature was maintained at 25 ± 1 ºC, and observed the fluorescence of the tryptophan 
residues of the protein (λex = 280 nm, λem = 340 nm).  The benzenesulfonamides of LRL 
do not quench or enhance the fluorescence of the tryptophan residues when bound to 
(CA)2.  ii) After the contents of the cuvette reached equilibrium (fluorescence signal did 
not change with time), we added a solution of ethoxzolamide (Kd
mono = 0.2 nM) to the 
cell.  iii) We observed a decrease in the fluorescence as mixing took place over a period 
of ~10 sec. This initial decrease in fluorescence is a result of the inner-filter effect—the 
more ethoxzolamide present in the sample the less light reaches the detector. iv) During 
and after the ~10 sec mixing period, the fluorescence signal decreases as LRL dissociates 
from the active sites of (CA)2 and is replaced by ethoxzolamide, which, unlike 
benzenesulfonamide, quenches the fluorescence of tryptophan residues of CA when 
bound in the active site.    
  The rates of dissociation of LSar4L from (CA)2 increase as the concentration of 
ethoxzolamide increases (Figure 3d).  We infer that LSar4L binds bivalently to (CA)2.  
We propose a mechanism consisting of several steps for LRL to dissociate from (CA)2 in 
the presence of ethoxzolamide (Scheme 2).  Ethoxzolamide competes with LRL for the   16 
unoccupied binding site of (CA)2·LRL
lin.  Hence, as the concentration of ethoxzolamide 
increases, the rate at which ethoxzolamide binds to the unoccupied binding site of 
(CA)2·LRL
lin (characterized by kon
ethox [ethox], Scheme 2) becomes larger than the rate  at 
which the unbound binding moiety of LRL binds to the unoccupied binding site of 
(CA)2·LRL
lin (characterized by kon
intra).  The combination of ethoxzolamide with the 
binding site of (CA)2 is effectively irreversible, and increases the rate of dissociation of 
LRL from (CA)2.  When the product (kon
ethox·[ethox]) is much larger than kon
intra, 
rebinding of (CA)2·LRL
lin to form (CA)2·LRL
cyc is prevented and LRL rapidly 
dissociates from (CA)2.   
  We also analyzed the dissociation of L and LEG3L—which we hypothesized to 
be too short to span the distance between binding sites of the dimer—from (CA)2 using 
the same assay. The presence of ethoxzolamide did not affect the rate of dissociation L 
and LEG3L from (CA)2  (Figure 3b and c).  A rate of dissociation that is independent of 
the concentration of ethoxzolamide is compatible with a mechanism for dissociation that 
involves a single dissociation event of the ligand from the active site—in other words, 
these results indicate that once L dissociates from (CA)2, it does not rebind.  Based on 
these results we include (CA)2·LRL
cyc in the mathematical model that we fit to data from 
the fluorescent displacement assay to obtain the free energy of bivalent binding in the 
following section.      
  Determination of Values of Kd
avidity for the Association of LRL’s with (CA)2 
Using a Fluorescence Displacement Assay.  We used a competitive fluorescence-based 
assay to estimate values of Kd
avidity for binding of bivalent sulfonamide ligands to (CA)2 
by competition with dansylamide (DNSA; Kd
mono ~240 nM) for the active sites of (CA)2   17 
(Figure 4).  We began with a concentration of DNSA (5 µM) sufficient to saturate 95% of 
the active sites of (CA)2 (25 nM), titrated this solution with bivalent ligand (LRL), and 
followed the disappearance of the fluorescence as the total concentration of LRL 
increased.   
  The titration is described by a thermodynamic scheme containing four (CA)2-
ligand complexes (i.e., (CA)2·(DNSA)2, (CA)2·LRL·DNSA, (CA)2·LRL
cyc, and 
(CA)2·(LRL)2) and three equilibria that connect them (K1, K2, and K3) (Figure 5a).  We fit 
the mathematical description of Figure 5a (eq S21 in Supporting Information) to the 
titration data using Kd
intra as the sole adjustable parameter (Table 1).  The Supporting 
Information details the mathematical description of Figure 5 and the derivation of 
equation S21.  We calculated values of Kd
avidty from Kd
intra (eq 10) and found that LSar4L 
was the tightest binding bivalent ligand (Figure 6). 
  Values of ΔG°avidity lie within a small range, but indicate that LSar4L is the 
tightest binder. The plot of ΔG°avidity as a function of the extended length shows two 
trends: the strength of binding increases as Γ increases from 30 to 45 Å, the strength 
reaches a maximum at Γ equal to 45 Å, and then the strength decreases as Γ increases 
from 45 to 70 Å (Figure 6).  Lundquist and Toone have speculated that the length of the 
linker between the binding moieties of a bivalent ligand should determine the free energy 
of its interaction with a bivalent protein.
32  In their view, bivalent ligands of less than 
ideal length can span the distance between two sites of a bivalent receptor but are too 
short to allow the binding moieties of the bivalent ligand to achieve simultaneously the 
optimal orientation in the binding sites.  They hypothesized that these “short” bivalent 
ligands will lead to diminished avidity because the sum of the enthalpies of the two   18 
interactions will be less than 2ΔH°mono.  Lundquist and Toone also suggested that the 
strength of the bivalent interaction should be at a maximum when the length of the linker 
is “exactly” the appropriate length (but not longer) to allow both binding moieties of the 
ligand and both subunits of the receptor to achieve simultaneously optimal orientations.  
Longer linkers, if the rotatable bonds in the linker are restricted upon the formation of the 
cyclic complex, diminish the strength of binding because of the unfavorable entropy of 
restricting rotatable bonds in the linker domain.  In our previous work with a covalently 
tethered system, we found that the free energy of association decreased as the length of 
tether connecting ligand to protein increased.
22  The behavior we observe, in this system, 
for increasing Γ beyond 45 Å is consistent with our previous work.  Without 
characterizing the enthalpic and entropic contributions to binding, however, we cannot 
evaluate the validity of the model of Lundquist and Toone;
32 although the trends we 
observe are consistent with their model. 
  Mixtures of (CA)2 and LSar4L form insoluble aggregates at concentrations 
needed for isothermal titration calorimetry.  We attempted to measure the enthalpy of 
interaction between LRL and (CA)2 using isothermal titration calorimetry (ITC).
33  We 
found that precipitates—which we detected as a milky-white suspension following the 
titration—are formed when (CA)2 (5 µM, required for ITC) is titrated with a solution of 
LRL (50 μM).  We infer from the formation of precipitates that intermolecular binding 
occurs at these concentrations to form protein-ligand complexes containing more than 
one (CA)2, although we cannot determine from the formation of precipitates alone the 
degree to which intermolecular binding competes with the intramolecular binding.  Since 
estimating values of Kd and ΔH° requires a thermodynamic model (e.g., one bivalent   19 
ligand binding to one—and only one—bivalent protein), it is impossible to use the data 
from ITC in this system to determine the enthalpic and entropic contributions to the 
bivalent interaction.  The formation of these precipitates is consistent with the range of 
effective molarities (2 to 20 µM) we estimated by fluorescence displacement assay; that 
is, when the total concentration of (CA)2 approaches the value of Meff, intermolecular 
interactions become increasingly favored over intramolecular interactions.   
 
CONCLUSIONS 
  (CA)2 is an excellent model for studying bivalency in antibodies.  This paper 
describes a model bivalent receptor inspired by the structure of bivalent antibodies.  
Dimers of CA are versatile models of bivalency in IgG and IgE because they access a 
wealth of background information and assays available for CA that is not available for 
antibodies, and because dimers of CA are readily available.  This model system allowed 
us to compare the thermodynamics of binding of bivalent ligands to our previous work 
with a tethered ligand-CA system 
22 and to dimers of CA binding to SAMs.
3  We plan to 
synthesize dimers of CA incorporating Fc mimics to explore the role of Fc in the 
thermodynamics of binding.  We believe additional synthetic dimers, in addition to 
dimers of carbonic anhydrase, can be developed to explore in greater detail the structure-
function relationships for antibodies.   
  ΔG°avidity is weaker than simple theory predicts. The free energy of bivalent 
binding (ΔG°avidity) for the tightest binding bivalent ligand, LSar4L, is much lower than 
predicted based on two monovalent interactions of binding. The simplest level of theory 
predicts that the change in free energy for the bivalent association of (CA)2 to bivalent   20 
ligands (ΔG°avidity) would be twice the change in enthalpy for the monovalent interaction 
(ΔH°mono) plus TΔS°mono for a single monovalent interaction (eq 1).
8  The values of the 
enthalpy and entropy of binding for monomeric CA to benzenesulfonamide 6 are ΔH°mono 
= –9.2 kcal mol
-1 and TΔS°mono = 0.4 kcal mol
-1.
34  This simple theory estimates a value 
of ΔG°avidity = -18.8 kcal mol
-1 for (CA)2 and LSar4L; a value that is ~ 4 kcal mol
-1 more 
favorable that the value we observed.  The linker could, in principle, influence (favorably 
or unfavorably) the free energy of the bivalent interaction by interacting with the surface 
of the protein, although we have established in previous studies that oligomers of 
sarcosine do not affect the free energy of interaction of arylsulfonamides by associating 
with the surface of HCA.
26 Unfortunately, we have not been able to obtain a value for the 
enthalpy for the binding of these ligands to (CA)2, because precipitates are formed at the 
concentrations required for calorimetry.  The thermodynamic basis for the difference 
between the measured values of ΔG°avidity and those predicted by equation 1, therefore, 
has not yet been defined. 
  Variation in ΔG°avidity with the length of the linker is surprisingly small.  The 
free energy of the bivalent interaction becomes more favorable as the length of the linker 
increases until it reaches a minimum at n = 4. For ligands with longer linkers, the free 
energy monotonically increases (i.e., becomes less favorable) with increasing length of 
the linker.     
  The values of ΔG°avidity for the bivalent ligands (LRL) differ by less than 2 kcal 
mol
-1 between the tightest binding bivalent ligand (LSar4L) and the weakest binding 
bivalent ligand (LSar10L).  The weak dependence of the strength of association on the 
length of the linker is consistent with our previous studies of intramolecular binding,   21 
where variations in oligo(ethylene glycol) linkers from n = 0 to 20 resulted in changes of 
binding of ~ 2 kcal mol
-1.  Interestingly—albeit, perhaps, coincidentally—the variation of 
the values of ΔG°avidity with increasing length of the sarcosine linker of the ligand is 
compatible with the thermodynamic analysis of Lundquist and Toone.
32  The length of 
the linker affects the strength of binding, but length alone cannot account for the ~4 kcal 
mol
-1 difference between the value of ΔG°avidity predicted by theory (-19 kcal mol
-1) and 
the values of ΔG°avidity we measured (-15 kcal mol
-1). 
  Tight-binding multivalent ligands can be synthesized with “long”, flexible 
linkers.  Consistent with our previous work and the work of others, the results of this 
paper suggest that flexible bivalent ligands that are longer than the spacing between the 
binding sites of the receptors can still bind tightly to multivalent proteins.
35  A bivalent 
ligand (LSar4L) with a linker of “optimal” length, in this system, gave ~2 kcal mol
-1 
more favorable free energy than a bivalent ligand 25 Å longer.  The effort required to 
“optimize” the length of the linker may not be worth the effort to obtain an increase in the 
strength of binding of ~2 kcal mol
-1.  
 
EXPERIMENTAL SECTION 
  General Methods. Chemicals we purchased from Aldrich, Alfa Aesar, and 
Novabiochem.  NMR experiments were carried out on a Varian INOVA 500 MHz 
spectometer.  Isothermal titration calorimetry (ITC) was performed using a VP-ITC 
microcalorimeter (MicroCal).  UV-vis spectroscopy was conducted on a Hewlett- 
Packard 8453 spectrophotometer.  Analytical HPLC was run on a Varian instrument with 
a C18 column, 5 µm (4.6 × 250 mm), from Vydac using a linear gradient of water with   22 
0.1% TFA (A) followed by acetonitrile containing 0.08% TFA (B), at a flow rate of 1 mL 
min
-1 (UV detection at 218 and 280 nm).  Preparative reverse-phase HPLC was 
performed using a Varian HPLC instrument equipped with a C18 column, 5 µm (22 × 
250 mm), from Vydac at a flow rate of 15 mL min
-1 with UV detection at 218 and 280 
nm.  Fluorescence measurements were performed on Perkin Elmer LS 50 B Fluorimeter 
(kinetic assay) and on a Molecular Devices SpectraMax Gemini XS instrument for 
detection at 460 nm (for DNSA binding assays). 
  Synthesis of Monovalent and Bivalent Sulfonamides.  All ligands, except 
LEG3L, were synthesized using standard Fmoc chemistry by stepwise solid-phase 
methodology, according to published procedures.
36  The crude mixtures containing 
ligands were purified by preparative reverse-phase HPLC and the appropriate fractions 
lyophilized.  Purity and molecular weight were consistent with the proposed structure as 
assessed by analytical RP-HPLC and ESI-HRMS.  L: ESI-HRMS m/z found 400.1655 
Da; calcd 400.1672 Da.  LEG3L: ESI-HRMS m/z found 537.1115 Da; calcd 537.1090 
Da.  LSar0L: ESI-HRMS m/z found 640.2209 Da; calcd 640.2223.  LSar2L: ESI-HRMS 
m/z found 782.2980 Da; calcd 782.2966 Da.  LSar4L: ESI-HRMS m/z found 924.3718 
Da; calcd 924.3708 Da.  LSar6L: ESI-HRMS m/z found 1066.44 Da; calcd 1066.44 Da.  
LSar8L: ESI-HRMS m/z found 1208.52 Da; calcd 1208.52 Da.  LSar10L: ESI-HRMS 
m/z found 1350.59 Da; calcd 1350.59 Da. 
  Quantitation of Stock Solutions of Arylsulfonamide Ligands.  Solutions were 
prepared to ~20 mM by weighing the solid bivalent ligand then adding the appropriate 
amount of DMSO-d6.  Stock solutions were diluted 1:10 with 2.00 mM maleic acid 
standard in DMSO-d6, which were prepared gravimetrically.  Proton resonances from the   23 
arylsulfonamide were normalized relative to those from maleic acid (allowing a 10 s 
delay between pulses) to determine the concentration of the stock solutions accurately. 
  Analytical Ultracentrifugation (AUC).  The molecular weight of (CA)2  with 
and without added LRL in solution was estimated by sedimentation equilibrium on a 
Beckman XL–I ultracentrifuge.  Concentrations of (CA)2 were fixed at 0.925 µM. 
Samples were dissolved in 10 mM phosphate buffer (pH 7.40), containing 137 mM NaCl 
and 2.7 mM KCl. The samples were centrifuged at 6,000, 9,000 and 12,000 rpm for 22 
hours at 25 °C before absorbance scans were performed.  Data obtained at 25 °C were fit 
globally to an equation that describes the sedimentation of a homogeneous species using 
XL-A/XL-I Data Analysis software version 6.03 based on Origin software by OriginLab 
Software Inc. 
  Kinetic assay.  A solution of (CA)2 (16.7 nM) and bivalent ligand (160 nM) was 
prepared in 20 mM PBS (pH 7.4) and centrifuged to remove traces of dust.  A 2 mL 
portion of solution was transferred to a quartz cuvette and the cuvette placed in a Perkin 
Elmer LS 50 B Fluorimeter.  The solution was stirred and temperature was maintained at 
25 ± 1 ºC.   Following equilibration, the fluorescence of the tryptophan residues of the 
protein (λex = 280 nm, λem = 340 nm) was followed as a function of time.  When the 
fluorescence signal did not change with time (a stable baseline was reached), 100 uL of a 
solution of ethoxzolamide (Kd
mono = 0.2 nM in PBS at pH 7.4) was added to the stirred 
solution of (CA)2 and ligand.  The time immediately following the brief mixing period 
(~10 sec) was taken as time zero (t = 0 sec.).  The fluorescence signal was normalized 
from time zero to the end of the experiment.        24 
  Determination of Avidities for the Binding of LRL to (CA)2.  To the wells of a 
black 96 microwell plate was added L or LRL (which was diluted serially across the 12 
wells of the plate) followed by a solution of (CA)2 (25 nM final concentration) in a final 
volume of 200 µL of 20 mM sodium phosphate pH 7.4.  The covered plate was incubated 
at 25 ºC for more than 2 h.  The intensity of the fluorescence was measured ~5 times (λex 
= 290 nm, λem = 460 nm, with a 455 nm cut-off filter).  The intensities were fit to eq S21 
(Supporting Information).       
  Crystallization of (CA)2.  Crystals were grown by vapor diffusion from a 
reservoir solution of 2.0 M ammonium sulfate at pH 8.8 (bicine). The crystals appeared 
as thin plates and grew to their full size (approximately 0.4 mm x 0.4 mm x 0.1 mm) in 
about 2 weeks at 4 °C. A crystal was captured in a nylon loop, transferred to a 20% 
glycerol/85% reservoir cryoprotectant solution briefly, rapidly frozen in a liquid nitrogen 
bath, and finally mounted in a cryo-stream (Oxford Cyrosystems). The X-ray source was 
a rotating copper anode, and diffraction data were collected on an RAXIS IV (Rigaku) 
instrument. The data set used in this structure was measured from a single crystal. The 
data describing these crystals appears in the supporting information. 
  Molecular Modeling.  Models of (CA)2 with bivalent ligands were prepared 
using the Molecular Operating Environment (MOE) program available from Chemical 
Computing Group, Inc.  The models of the dimer-ligand complexes were constructed 
using the coordinates of the crystal structure of (CA)2 and bivalents ligands constructed 
within MOE.  Two Zn-N bonds were created between the sulfonamides of the ligands 
and the zinc atoms in the active sites of the dimer.  The internal coordinates of the CA 
monomers were fixed and the energy of the complex was minimized using the AMBER   25 
force field allowing the bonds within bivalent ligand and the linker joining the monomers 
of CA to rotate.  A pdb file of the structure with the minimum energy was saved and 
rendered in Pymol.     
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Scheme 1.  Thermodynamic schemes describing the binding of monovalent ligands (L) to 
monovalent carbonic anhydrase CA and bivalent benzensulfonamide ligands (LRL) to a 
synthetic dimer of carbonic anhydrase (CA)2.  a) The binding of CA to a monovalent 
ligand in solution (L) forms a receptor-ligand complex (CA·L) that is characterized by 
the dissociation constant Kd
mono.  b) The binding of a ligand covalently attached to CA by 
a flexible tether to the binding site is characterized by the unitless dissociation constant 
Kd
intra.  c) The association of (CA)2 to two ligands (L*) on a surface can be 
conceptualized as a process involving two steps.  The initial step—the association of 
(CA)2 to L*—is characterized by dissociation constant Kd′ 
surf.  The second step—the 
association of an additional ligand to the unbound active site of (CA)2 forms a complex 
consisting of one (CA)2 and two ligands (L*·(CA)2·L*)—is characterized by dissociation 
constants Kd ″ 
surf.  The avidity (Kd
avidity surf) characterizes the strength of (CA)2 binding to 
L* in the form of L*·(CA)2·L*.  d) The association of a bivalent ligand (LRL) to a dimer 
of CA (CA2) can be conceptualized as a process involving two steps.  The initial step—
the association of one binding moiety of LRL to one binding site of CA2 to form the 
“open” complex (CA)2·LRL
lin —is characterized by the intermolecular dissociation 
constant ¼ Kd
inter.  The second step—the intramolecular association of the unoccupied 
binding site of (CA)2·LRL
lin to the second binding moiety of LRL to form the cyclic 
complex (CA)2·LRL
cyc—is characterized by the intramolecular dissociation constant 2 
Kd
intra.  The overall strength of binding between (CA)2 and LRL is characterized by 
Kd
avidity.   
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Figure 1. Crystal structures and molecular models of an IgG, and of (CA)2 with and 
without bivalent ligands.  All structures are rendered at the same scale.  a) X-ray crystal 
structure of a monoclonal murine IgG1 specific for phenolbarbital depicted as a multi-
colored ribbon diagram (the ribbon diagram was generated using PyMol and the atomic 
coordinates: PDB 1IGY).  b) X-ray crystal structure of (CA2) with the Zn
2+ ions of the 
active site rendered as magenta spheres.  The ethylene-glycol (EG) cross-linker joining 
the two monomers of CA is illustrated as atom colored sticks and outlined with a 
rectangle with dashed lines.  c)  Molecular model—not an X-ray crystal structure—of 
(CA)2 with LSar0L  docked in the active sites of (CA)2, to show a possible geometry for 
a bridging ligand.  The bivalent ligand LSar0L is rendered as atom colored spheres.  The 
structure of the protein is based on the X-ray crystal structure.  Details on the 
construction of the model are included in the Experimental section.  d) Molecular model 
of (CA)2 with LSar4L docked in the active sites.  e) Molecular model of (CA)2 with 
LSar10L docked in the active sites.  
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b) 
a) 
c) 
d) 
e)   32 
Chart 1.   
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Figure 2. Sedimentation equilibrium experiments of CA and (CA)2
 
 with and without 
added bivalent ligand as observed at 280 nm and 25 ºC. a) The hollow circles are 
experimental data for 925 nM (CA)2 without added LRL, and the line is the fit for a 
single ideal species. The molecular weight estimated by non-linear curve fitting of the 
data is 58 ± 4 kDa and the molecular weight (MW) determined by ESI-MS was 58.385 
kDa. b) The hollow circles are experimental data for 925 nM (CA)2
  with 1 µM LSar4L.  
The molecular weight estimated from non-linear curve fitting of the data is 54 ± 1 kDa.  
c) Plot of the estimated values of MW as determined from sedimentation equilibrium 
experiments, as a function of the maximum distance between the two nitrogen atoms of 
the sulfonamide functional groups of the bivalent ligand (Γ is the extended length).  The 
solid circles correspond to the best-fit values for MW calculated from non-linear curve 
fitting of the data, and the error bars correspond to the 95% confidence intervals from the 
non-linear fit.  The solid black line corresponds to the MW obtained from adding the 
molecular weight of (CA)2 to that of the ligand.  These data are summarized in Table S1 
and data included in the Supporting Information.  
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Figure 3.  Change in fluorescence (λex = 280 nm, λem = 340 nm) as benzenesulfonamide 
ligands dissociate from the active sites of (CA)2 (16.7 nM) and are replaced by 
ethoxzolamide (ethox, Kd = 0.2 nM) which quenches the fluorescence of (CA)2.  a) This 
plot shows the three phases of kinetic assay: i) Equilibration of the solution of (CA)2 and 
ligand in buffer.  ii) Addition of a solution of ethoxzolamide to the stirred solution of 
(CA)2 is accompanied by a reduction in fluorescence due to the inner filter effect.  The 
mixing is complete in ~10 sec. iii) The fluorescence decreases as the ligand dissociates 
from the active sites of (CA)2 and is replaced by ethoxzolamide.  Inset: The change in 
fluorescence as a solution of (CA)2 (16.7 nM) is equilibrated then a solution of 
ethoxzolamide (100 nM, Kd = 0.2 nM) is added. b) Stacked plot of the normalized 
fluorescence (λex = 280 nm, λem = 340 nm) of a solution of (CA)2 (16.7 nM) and L (160 
nM) when ethoxzolamide (5, 10, and 15 µM) is added.  These data are corrected for the 
inner-filter effect and normalized.  c) Stacked plot of the normalized fluorescence of a 
solution of (CA)2 (16.7 nM) and LEG3L (160 nM) when ethoxzolamide (5, 10, and 15 
µM) is added.  d) Normalized fluorescence of a solution of (CA)2 (16.7 nM) and LSar4L 
(160 nM) when ethoxzolamide (6.25, 12.5, 25, 50, and 100 µM) is added.  The solid 
shapes represent the data and the solid lines are an aid to the eye.    36 
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Scheme 2.  Kinetic scheme describing the dissociation of a bivalent ligand (LRL) from 
(CA)2 in the presence of ethoxzolamide (◄).  
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Figure 4.  Titration of (CA)2  with monovalent benzenesulfonamide L and  bivalent 
benzenesulfonamide ligands LRL. (CA)2 (25 nM) was equilibrated with 5 µM 
dansylamide 2 in 20 mM sodium phosphate buffer (pH 7.4) and different amounts of L or 
LRL. The fluorescence of the solution was monitored with a plate reader (λex = 290 nm, 
λem = 460 nm). The temperature was maintained at 25 ºC.    Each datum represents the 
average of three independent experiments, and the error bars represent the 90% 
confidence interval according to t-statistics.  The error bars have been removed from 
several sets of data for clarity but are similar to those shown.  The solid lines represent 
the best-fit line as determined from non-linear curve-fitting of eq S21 to each set of data 
(Supporting Information). 
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Figure 5.  Thermodynamic scheme and simulations describing the model used to analyze 
the fluorescence titration experiments. a) The thermodynamic scheme comprises three 
equilibria characterized by three equilibrium constants (K1, K2, and K3) and four species 
that contain a dimer of CA (i.e., (CA)2·(DNSA)2, (CA)2·LRL·DNSA, (CA)2·LRL
cyc, and 
(CA)2·(LRL)2).  b) Simulation of the normalized concentrations of species obtained from 
titrating a solution of (CA)2 (25 nM) and dansylamide (DNSA, 5 µM) with different 
concentrations of LSar4L (Kd
intra = 0.0007 unitless).  The concentration of the cyclic 
species (CA)2·LRL
cyc increases until a maximum is reached, as the total concentration of  
LSar4L is increased (from left to right).  The concentration of (CA)2·LRL
cyc then 
decreases as the concentration of unbound  LSar4L is increased, which competes for the 
active sites of LSar4L.  c) Simulation of the normalized concentrations of species 
obtained from titrating a solution of (CA)2 (25 nM) and dansylamide (5 µM) with 
LSar10L (Kd
intra = 0.0096 unitless).       
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Figure 6. Plot of ΔG°inter and ΔG°avidity for the binding of monovalent (L) and bivalent 
benzenesulfonamide ligands (LRL) to a synthetic dimer of CA (CA)2 as a function of the 
extended length of the linker (Γ, Å).  The monovalent ligand L does not have an extended 
length (Γ undefined), but it is included for comparison.  The hollow circles are values of 
ΔG°inter  (axis on the left side) and represent the ligands (L and LEG3L), which do not 
bind bivalently to (CA)2.  The solid circles are values of ΔG°avidity (axis on the right side) 
and represent the series of bivalent ligands (LSarnL), which bind bivalently to (CA)2.  
The labels correspond to the number of sarcosines units (n) in the linker.  All values are 
the average of three or more independent experiments and the errors bars correspond to 
90% confidence intervals according to t-statistics. 
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